Genetic and Molecular Differences in Head and Neck Cancer Based on Smoking History

被引：0
作者：
Jiang, Rong [1 ,2 ]
Gao, May Z. [3 ]
Chen, Meng [4 ]
Weatherspoon, Darien J. [5 ]
Watts, Tammara L. [1 ,2 ]
Osazuwa-Peters, Nosayaba [1 ,2 ,4 ,6 ,7 ]
机构：
[1] Duke Univ Sch Med, Dept Head & Neck Surg & Commun Sci, 40 Duke Med Cir,Duke South Orange Zone 4212,DUMC 3, Durham, NC 27710 USA
[2] Duke Univ, Duke Canc Inst, Durham, NC USA
[3] Duke Univ Sch Med, Durham, NC USA
[4] Duke Univ Sch Med, Duke Global Hlth Inst, Durham, NC USA
[5] Univ Maryland, Dept Dent Publ Hlth, Sch Dent, Baltimore, MD USA
[6] Duke Univ, Sch Med, Dept Populat Hlth Sci, Durham, NC USA
[7] JAMA Otolaryngol Head & Neck Surg, Divers Equ & Inclus, St Louis, MO USA
来源：
JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY | 2025年
关键词：
SQUAMOUS-CELL CARCINOMA; AMPLIFICATION; 11Q13; BIOMARKERS; PROGNOSIS; VARIANTS; RISK; FADD;
D O I：
10.1001/jamaoto.2024.5409
中图分类号：
R76 [耳鼻咽喉科学];
学科分类号：
100213 ;
摘要：
Importance Up to 80% of survivors of head and neck squamous cell carcinoma (HNSCC) currently or previously smoked. Thus, tobacco use is a major modifiable risk factor for HNSCC, even in the era of human papillomavirus (HPV)-associated disease. However, how smoking underlies chromosomal and epigenetic changes that are associated with HNSCC outcomes remains unclear. Objective To characterize genetic and molecular differences and associated biological pathways in patients with HNSCC based on smoking history. Design, Setting, and Participants This retrospective cohort study included patients with a confirmed diagnosis of HNSCC from the Cancer Genome Atlas via cBioPortal data independent of HPV status. Data were analyzed between April 2023 and May 2024. Main Outcomes and MeasuresSmoking history was defined as individuals who smoked (currently or previously) compared with nonsmokers (never smoked). Genetic and molecular differences of interest were single nucleotide variation, copy number alteration, DNA methylation, and messenger RNA (mRNA) expression. Accounting for multiple testing, we reported the false discovery rate (FDR), with a statistically significant FDR of 0.05 or less. Potential functions and pathways were investigated using the Panther classification system, and the Fisher exact test was used for overrepresentation, using the Reactome pathway dataset as a guide. Associations between smoking-related genetic alterations and overall survival were analyzed using log-rank tests. Results Of 511 participants, 135 (26.4%) were female, and the mean (SD) age was 60.8 (11.9) years. People who smoked (389 [76.1%]) demonstrated significantly enriched copy number alterations on 9 genes located on chromosome 11q13 compared with nonsmokers (122 [23.9%]; FDR, 0.044-0.046). Two genes, FADD and CTTN, were significantly highly methylated in nonsmokers. Also, PPFIA1, FGF19, CCND1 and LTO1 were highly expressed in mRNA in those who smoked, while FADD mRNA expression was negatively correlated with FADD DNA methylation in nonsmokers (Pearson r = -0.53; 95% CI, -0.59 to -0.49) and those who smoked (Pearson r = -0.57; 95% CI, -0.63 to -0.51). People who smoked with altered FADD had higher risk of dying than those with FADD unaltered (hazard ratio, 1.40; 95% CI, 1.004-1.96). Pathway analysis showed the significant genes were collectively associated with cellular processes and biological regulations, including olfactory signaling and the PI3K/AKT network. Conclusion and Relevance The results of this cohort study suggest that there may be patterned genetic and molecular differences in patients with HNSCC based on smoking history, especially genes located on chromosome 11q13. These genomic differences due to smoking make smoking a modifiable risk factor for HNSCC outcomes.
引用
收藏
页码：379 / 388
页数：10
相关论文
共 57 条
  • [1] Johnson D.E., Burtness B., Leemans C.R., Lui V.W.Y., Bauman J.E., Grandis J.R., Head and neck squamous cell carcinoma, Nat Rev Dis Primers, 6, 1, (2020)
  • [2] Siegel R.L., Miller K.D., Wagle N.S., Jemal A., Cancer statistics, 2023, CA Cancer J Clin, 73, 1, pp. 17-48, (2023)
  • [3] Sturgis E.M., Cinciripini P.M., Trends in head and neck cancer incidence in relation to smoking prevalence: An emerging epidemic of human papillomavirus-associated cancers?, Cancer, 110, 7, pp. 1429-1435, (2007)
  • [4] Cohen N., Fedewa S., Chen A.Y., Epidemiology and demographics of the head and neck cancer population, Oral Maxillofac Surg Clin North Am, 30, 4, pp. 381-395, (2018)
  • [5] Berthiller J., Straif K., Agudo A., Low frequency of cigarette smoking and the risk of head and neck cancer in the INHANCE consortium pooled analysis, Int J Epidemiol, 45, 3, pp. 835-845, (2016)
  • [6] Hashibe M., Brennan P., Chuang S.C., Interaction between tobacco and alcohol use and the risk of head and neck cancer: Pooled analysis in the International Head and Neck Cancer Epidemiology Consortium, Cancer Epidemiol Biomarkers Prev, 18, 2, pp. 541-550, (2009)
  • [7] Anantharaman D., Muller D.C., Lagiou P., Combined effects of smoking and HPV16 in oropharyngeal cancer, Int J Epidemiol, 45, 3, pp. 752-761, (2016)
  • [8] Kawakita D., Hosono S., Ito H., Impact of smoking status on clinical outcome in oral cavity cancer patients, Oral Oncol, 48, 2, pp. 186-191, (2012)
  • [9] Osazuwa-Peters N., Adjei Boakye E., Chen B.Y., Tobo B.B., Varvares M.A., Association between head and neck squamous cell carcinoma survival, smoking at diagnosis, and marital status, JAMA Otolaryngol Head Neck Surg, 144, 1, pp. 43-50, (2018)
  • [10] Van Heest T., Rubin N., Khariwala S.S., Persistent tobacco use after treatment for head and neck cancer, JAMA Otolaryngol Head Neck Surg, 148, 7, pp. 597-603, (2022)
123456